LEAD PROGRAMME LIRAGLUTIDE EFFECT AND ACTION IN DIABETES
USPTO Trademark Record · Serial No. 79025194
Trademark details
It was initially claimed by Novo Nordisk A/S on 20060307.
That brand applies to the following goods and services:Printed newsletters, journals and magazines related to medical studies and research regarding pharmaceutical preparations for the treatment of diabetes-related diseases and disorders, Medical and scientific research, namely, conducting clinical trials and studies relating to pharmaceutical preparations for the treatment of diabetes-related diseases and disorders, and providing scientific information on the efficacy of pharmaceutical preparations for the treatment of diabetes-related diseases and disorders, Providing medical information on the efficacy of pharmaceutical preparations for the treatment of diabetes-related diseases and disorders.
Currently that trademark is represented by trademark attorney(s): Keith Barritt.
You can learn more about that trademark on the USPTO website: View the USPTO record
Services available
Questions about this trademark?
If you have questions or issues related to the LEAD PROGRAMME LIRAGLUTIDE EFFECT AND ACTION IN DIABETES trademark — or to trademarks in general — our trademark attorneys can help. No appointment needed: call us or request a free estimate.
Register a Trademark Get a Free Estimate
